Polycythemia Vera
For treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea, intervene with Jakafi to achieve durable count control.
Myelofibrosis
For treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults, intervene with Jakafi at diagnosis.
Acute Graft-Versus-Host Disease
For treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older, intervene with Jakafi.
Experience with Jakafi since FDA approval1*
MORE THAN 30,000 PATIENTS TREATED
*Estimated total patients treated with commercially available Jakafi in the US since 2011.1
Reference
Indications and Usage
Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high‐risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid‐refractory acute graft‐versus‐host disease (GVHD) in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
You are now leaving the Jakafi.com website.
You are now leaving the Jakafi.com website. This link will take you to a site that is not owned or maintained by Incyte Corporation, and Incyte is not responsible for the information contained on third party sites.